tirzepatide surpass trials versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial Tirzepatide: First Approval | Drugs

They return when symptoms worsen

Tirzepatide can produce dramatic results, with clinical trials showing average weight loss of 15 to 22 percent of body weight, but some of that loss comes from lean tissue rather than fat

Counsel on dose escalation schedule, side effects and red-flag symptoms

Due to changes in your digestive system and how your body metabolizes drugs, you may need a lower dose than what's typically recommended on the packaging

These cards can lower your monthly out-of-pocket expenses for medications, sometimes as low as $0 to $25 per month

Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement